Abbott CEO: Concerns About GLP-1 in Medtech Are Overblown

Senior woman using a continuous glucose monitoring device to manage type 2 diabetes. .png

There has been a lot of noise in recent weeks surrounding the GLP-1 drugs and their ripple effect on medical technology, but Abbott CEO Robert Ford says these concerns are overblown. level. In fact, Ford remained optimistic Tuesday morning when discussing the potential relationship between the GLP-1 drug and medical technology. Initially approved to treat … Read more